Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | TYK2 | P29597 | 4/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 5/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24438190 | 0.83 | FYN (0.43) | FGFR3KDRKDM5BPIM1JAK2 | |
| SCHEMBL31131590 | 0.77 | JAK2 (0.47) | FGFR3KDRJAK2TYK2JAK1 | |
| SCHEMBL24439019 | 0.77 | JAK2 (0.39) | FGFR3KDRKDM5BPIM1JAK2 | |
| SCHEMBL2574412 | 0.76 | MAPK1 (0.40) | FGFR3KDRKDM5BPIM1FLT3 | |
| SCHEMBL2561514 | 0.76 | CHEK1 (0.48) | KDM5BPIM1JAK2TYK2JAK1 | |
| SCHEMBL14863891 | 0.76 | TNK2 (0.38) | KDM5BPIM1JAK2TYK2JAK1 | |
| Hydrochloric Acid SCHEMBL14863956 | 0.75 | CHEK1 (0.47) | KDM5BPIM1JAK2TYK2JAK1 | |
| SCHEMBL2574123 | 0.75 | GRIA1 (0.33) | — | |
| SCHEMBL2571304 | 0.74 | PIM1 (0.39) | KDM5BPIM1JAK2TYK2JAK1 | |
| SCHEMBL12285221 | 0.74 | CHRM1 (0.40) | FGFR3KDRPIM1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250034150-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-4429770-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4244223-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | Biogen MA Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023086521-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086521-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-2766368-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | Array Biopharma Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140228349-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | ARRAY BIOPHARMA, INC. | 2014-08-14 | — | — | US | disclosed |
| US-20140228349-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | ARRAY BIOPHARMA, INC. | 2014-08-14 | — | — | US | disclosed |
| US-20140228349-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | ARRAY BIOPHARMA, INC. | 2014-08-14 | — | — | US | disclosed |
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013055645-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | ARRAY BIOPHARMA INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2558468-A1 | 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | Array Biopharma, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130146-A1 | 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | JAK1, JAK3, JAK2 | FGFR3 513/4885KDR 834/4885KDM5B 1149/4885 |
| US-20140228349-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES | JAK1, JAK3, JAK2 | FGFR3 665/4885KDR 1109/4885KDM5B 1575/4885 |
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BTK, SYK, LYN | FGFR3 1836/4885KDR 549/4885KDM5B 1000/4885 |
| US-20250034150-A1 | BTK INHIBITORS | BTK, SYK, LYN | FGFR3 942/4885KDR 437/4885KDM5B 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.